Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial

  • Angeliki Papadaki
    Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies University of Bristol Bristol UK
  • Miguel Ángel Martínez‐González
    University of Navarra, Department of Preventive Medicine and Public Health Faculty of Medicine IdiSNA Pamplona Spain
  • Angel Alonso‐Gómez
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Javier Rekondo
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Jordi Salas‐Salvadó
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Dolores Corella
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Emilio Ros
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Montse Fitó
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Ramon Estruch
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • José Lapetra
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Antonio García‐Rodriguez
    Department of Preventive Medicine University of Malaga Malaga Spain
  • Miquel Fiol
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Lluís Serra‐Majem
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Xavier Pintó
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Miguel Ruiz‐Canela
    University of Navarra, Department of Preventive Medicine and Public Health Faculty of Medicine IdiSNA Pamplona Spain
  • Monica Bulló
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Mercè Serra‐Mir
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Jose V. Sorlí
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain
  • Fernando Arós
    CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) Instituto de Salud Carlos III (ISCIII) Madrid Spain

抄録

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>The aim of this study was to evaluate the effect of the Mediterranean diet (MedDiet) on the incidence of heart failure (HF), a pre‐specified secondary outcome in the PREDIMED (PREvención con DIeta MEDiterránea) primary nutrition‐intervention prevention trial.</jats:p></jats:sec><jats:sec><jats:title>Methods and results</jats:title><jats:p>Participants at high risk of cardiovascular disease were randomly assigned to one of three diets: MedDiet supplemented with extra‐virgin olive oil (EVOO), MedDiet supplemented with nuts, or a low‐fat control diet. Incident HF was ascertained by a Committee for Adjudication of events blinded to group allocation. Among 7403 participants without prevalent HF followed for a median of 4.8 years, we observed 29 new HF cases in the MedDiet with EVOO group, 33 in the MedDiet with nuts group, and 32 in the control group. No significant association with HF incidence was found for the MedDiet with EVOO and MedDiet with nuts, compared with the control group [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.41–1.13, and HR 0.92; 95% CI 0.56–1.49, respectively].</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In this sample of adults at high cardiovascular risk, the MedDiet did not result in lower HF incidence. However, this pre‐specified secondary analysis may have been underpowered to provide valid conclusions. Further randomized controlled trials with HF as a primary outcome are needed to better assess the effect of the MedDiet on HF risk.</jats:p><jats:p><jats:bold>Trial registration:</jats:bold> ISRCTN35739639.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ